A New Frontier in Metabolic Disease: GLP-1 Pioneer Backs Retroviral Senolytics

COPENHAGEN, Denmark – November 12, 2026 – The discovery of glucagon-like peptide-1 (GLP-1) in the late 1980s fundamentally altered the trajectory of metabolic medicine, laying the groundwork for blockbuster drugs like semaglutide and liraglutide that now dominate the treatment of type 2 diabetes and obesity. Now, Professor Jens Juul Holst, the renowned co-discoverer of GLP-1, is turning his attention to an entirely different and radically unconventional therapeutic frontier: ancient retroviruses embedded in human DNA.

HERVolution Therapeutics, a Copenhagen-based biotechnology company, announced today the appointment of Professor Holst to its Scientific Advisory Board. The move signals a powerful scientific endorsement for the company's lead program, IPT-001, an experimental immunotherapy designed to clear senescent cells by targeting human endogenous retrovirus K (HERV-K).

"Jens Juul Holst is one of the defining figures in metabolic science, and his decision to join our Scientific Advisory Board is a strong endorsement of the biology behind IPT-001," said J. Robert Coleman, CEO of HERVolution Therapeutics. "Few people understand the physiology of metabolic disease as deeply as Jens. His insight will be invaluable as we translate HERV-K biology into a new therapeutic approach and prepare to enter the clinic."

Beyond GLP-1: Targeting the Root of Metabolic Aging

The GLP-1 receptor agonist market is currently experiencing unprecedented growth, projected by industry analysts to reach approximately $200 billion by 2030. Pharmaceutical giants like Novo Nordisk and Eli Lilly have revolutionized weight management and glycemic control. However, these therapies primarily address the downstream physiological symptoms of metabolic dysfunction rather than its underlying cellular causes.

Professor Holst's alignment with HERVolution suggests a growing recognition among leading scientists that the next generational leap in metabolic care will require interventions that target cellular aging itself.

"The interplay between cellular senescence, chronic inflammation, and insulin resistance is one of the most compelling frontiers in metabolic disease," Professor Holst stated. "HERVolution's approach of directing a targeted immune response against HERV-K-expressing senescent cells addresses that biology at its root. I look forward to contributing my experience in metabolic physiology and translational research to help shape the company's first-in-human program."

As humans age, damaged or stressed cells enter a state of permanent cell-cycle arrest known as cellular senescence. Often colloquially referred to as "zombie cells," they resist apoptosis and secrete a toxic cocktail of pro-inflammatory cytokines, chemokines, and proteases—a phenomenon known as the senescence-associated secretory phenotype (SASP). In metabolic tissues, the accumulation of these cells exacerbates chronic low-grade inflammation, directly driving beta-cell dysfunction and insulin resistance.

While GLP-1s stimulate insulin secretion and suppress appetite, a senolytic approach aims to clear the pathogenic zombie cells entirely, potentially restoring tissue health and reversing the progression from pre-diabetes to clinical type 2 diabetes.

Awakening Ancient Viruses: The Biology of HERV-K

The scientific premise underpinning HERVolution's pipeline reads like science fiction, yet it is grounded in a rapidly expanding body of peer-reviewed literature. Approximately 8% of the human genome consists of human endogenous retroviruses (HERVs)—genetic remnants of ancient viral infections that integrated into the DNA of our evolutionary ancestors millions of years ago.

For decades, these sequences were dismissed as dormant "junk DNA." However, recent research has revealed that while most HERVs are defective, certain families, particularly HERV-K (HML-2), remain remarkably intact. During the aging process and the onset of cellular senescence, the epigenetic mechanisms that normally suppress these ancient viral genes begin to fail.

As senescent cells lose their epigenetic silencing, HERV-K "wakes up." The cells begin transcribing viral proteins and even assembling virus-like particles (VLPs). This reactivation triggers an innate immune response that further entrenches the cell in a senescent state and amplifies the inflammatory SASP. Furthermore, extracellular HERV-K VLPs released from these cells can transfer to neighboring, healthy cells, inducing senescence in a paracrine manner and spreading metabolic dysfunction across tissues.

HERVolution has been actively building the clinical case for this mechanism. In July 2026, the company presented clinical data at the International Congress on Obesity demonstrating elevated HERV-K reactivation in human plasma samples from individuals with obesity. This evidence strongly links the ancient viral protein to the chronic inflammation and insulin resistance observed in metabolically unhealthy patients.

Reprogramming the Immune System

To combat this viral reactivation, HERVolution is developing IPT-001, a dual adenoviral (Ad) vector immune therapy. The challenge with targeting HERVs is that, because they are encoded in the human genome, the body's immune system naturally tolerates them. HERVolution's proprietary engineering platform overcomes this by rationally redesigning the HERV-K antigen, breaking immune tolerance and making the viral proteins visible to the immune system.

Once administered, IPT-001 is designed to train T-cells to seek out and destroy senescent cells expressing HERV-K, effectively acting as a senolytic insulin sensitizer.

"The success of GLP-1 therapies has created an incredibly high bar for new metabolic treatments," noted one independent biotechnology analyst familiar with the space. "To disrupt this market, you need a fundamentally different mechanism. If you can definitively prove that clearing HERV-K senescent cells reverses insulin resistance in humans, you are looking at an entirely new paradigm in endocrinology."

The senolytic field is already gaining momentum. First-generation small-molecule senolytics, such as dasatinib and quercetin, showed early promise but have faced hurdles regarding variable efficacy and off-target toxicity. Consequently, the industry is pivoting toward "precision senotherapy." Just last month, in October 2026, Immorta Bio announced the first human administration of its own investigational senolytic immunotherapy, SenoMune-0257. HERVolution's IPT-001 represents a highly specific, antigen-directed iteration of this broader industry trend.

Financially, the company is well-positioned to advance its pipeline. HERVolution has raised $18.2 million to date, anchored by an $11.7 million Series A round in December 2024 led by the Serum Institute of India (SII), with participation from the European Innovation Council Fund. This capital is actively funding cGMP manufacturing and IND-enabling studies.

A Broad Horizon: From Diabetes to Oncology

While Professor Holst's appointment explicitly highlights the metabolic applications of IPT-001, HERV-K reactivation is a hallmark of multiple age-related and severe diseases, granting HERVolution's platform significant pipeline-in-a-product potential.

In oncology, HERV-K is increasingly recognized as a clinically actionable tumor-associated antigen. In early 2026, the U.S. Food and Drug Administration cleared an Investigational New Drug application for a separate, third-party RNA cancer vaccine targeting the HERV-K envelope protein, validating the regulatory viability of the target. HERVolution itself is positioning IPT-001 for concurrent development in oncology, alongside its metabolic indications.

Furthermore, aberrant HERV-K expression has been heavily implicated in neurodegenerative conditions, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), suggesting that a successful HERV-K immunotherapy could eventually find applications far beyond the pancreas and adipose tissue.

With a projected 2027 timeline for initiating first-in-human clinical trials, HERVolution Therapeutics is entering a critical phase of development. The addition of Jens Juul Holst to its scientific brain trust not only provides invaluable physiological expertise but also signals to the broader biopharmaceutical industry that the next major breakthrough in metabolic disease might just come from the ancient viral ghosts hidden within our own DNA.